MedComm 润色咨询

MedComm

出版年份:暂无数据 年文章数:94 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:暂无数据 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

投稿信息

投稿信息
审稿费用
暂无数据
版面费用
暂无数据
中国人发表比例
2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%)
自引率
暂无数据
年文章数
94
期刊官网
点击查看 (点击次数:2216)
点击查看 (点击次数:1119次)
作者需知
点击查看 (点击次数:369次)
期刊简介
稿件收录要求

Aim of the journal

MedComm is a peer-reviewed, online open access journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance to human health. The journal emphasizes original findings that advance the understanding of pathogenesis or improve the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged.

Scope and topics (including keywords)

MedComm is interested in topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, nanotechnology and artificial intelligence. The journal focuses on clinical and experimental advances on disease characteristics, pathogenic mechanism and medical techniques.

Topics of interest include, but are not limited to:

  • Epigenetics, genomics, proteomics and metabonomics
  • Non-coding RNA in disease
  • Cell senescence and cell death
  • Cellular signal transduction
  • Gene therapy and gene editing
  • Cancer immunology and immunotherapy
  • Structural biology, chemical genomics and drug discovery
  • High-definition imaging
  • Artificial intelligence in medicine
  • Stem cells and regenerative medicine
  • Nanomedicine and drug delivery system
  • Early disease diagnosis and biomarkers
  • Clinical trials evaluating new treatments for cancer or other diseases